GEN Exclusives

More »

Tutorials

More »
Jun 1, 2010 (Vol. 30, No. 11)

Autoantibodies as Diagnostic Biomarkers

Readily Detectable Agents Are Suitable for Presymptomatic and Early Diagnosis of Disease

  • Conclusion

    Biomarkers must be both easy to detect and measure if they are to be used clinically. In addition, the use of a panel of biomarkers as opposed to a single biomarker can offer more robust and accurate results while minimizing the risk of false positives.

    As such, circulating autoantibodies represent a pertinent source of early diagnostic and presymptomatic biomarkers for a number of pathologies including certain cancers and autoimmune diseases.

    OGT has experience in the development of such panels using a number of different technologies. Core to the autoantibody area is Sense Proteomic’s functional protein array technology. This uses a BCCP fusion tag to provide the assurance that immobilized proteins are properly folded and hence native conformational epitopes are presented on the surface of each protein. As a result, the diagnostic autoantibody biomarker panels developed form  sensitive and highly selective pathology fingerprints.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Mindclones and Immortality

Is the idea of making a software copy of a human mind something in the realm of reality or science fiction?